Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Kalorama Reports | Early Toxicology Markets and Approaches

Early Toxicology Markets and Approaches

Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug.

Just twenty years ago, toxicology was something that was measured after a drug was developed. Traditional studies were performed in-vivo with animals, and required 20 to 100 grams of the candidate compound for a single set of evaluations. Intake of the compound was measured, and a series of toxicity tests were performed, including LD 50 and histological examinations of target organs. These tox tests were expensive, time-consuming and were only performed on drug candidates that had already passed all other criteria to become successful drugs. These studies were high information, but low throughput estimates of a candidate drug’s toxicology. Failures were common, and expensive. The goal was to find approaches that would predict toxicology at an earlier stage, and with less cost.

Various in vivo, in vitro, and in silico approaches have been evolving ever since. The objective of this report is to focus the reader’s attention on the issues and opportunities related to early tox testing in drug discovery, including:

quantification of the current and future markets for various segments and subsegments,

discussion of various big pharma approaches to early toxicology testing,

review of the emerging tools and techniques,

the views of interviewed experts in the field, and

a landscape of competitors and their product and service offerings.

The report begins with an overview of drug discovery, ADMET, and early tox testing. It continues with some of the ways big pharmas deal with early tox. The next four chapters deal with the markets for in-silico, in-vitro, and in-vivo early tox products, and with the suppliers of early tox services. Product, company and market information are provided in each of these chapters. Opinions of the experts on basic issues are provided in Chapter Seven. The report concludes with profiles of 30 representative suppliers, the products they provide and their approach to the market.

For the purposes of reporting market size and growth forecasts, the report segments the market into the following:

In Silico Approaches

Databases

Data Mining Tools

Modeling

In Vitro Assays and Platforms

Biochemical Assays

Cellular Assays

Instruments & Platforms

In Vivo Testing

Mice & Traditional Animals

Zebrafish Models

Other Animals

Human Microdosing

Early Tox Services

In Silico Services

In Vitro Services

In Vivo Services

Published: Jun 1, 2007

235 Pages

PDF Format
Table of Contents
Price: $3,495.00 / €2,338.16

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions